In development: Guidance, quality standards and advice
Showing 301 to 308 of 308
| Title | Type | Expected publication date |
|---|---|---|
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Women's and reproductive health guidelines | NICE guideline | TBC |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance |